# PATENT COOPERATION TREATY

# **PCT**

# Translation INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		FOR FURTHER	ACTION	See Form PCT/IPEA/416		
P03-0030PCT						
International application No.			date (day/month/year)	Priority date (day/month/year)		
	P2004/0041			26.03.2003		
	Patent Classification (	IPC) or national classification and	d IPC			
Applicant PHARM	ADESIGN, I	NC.				
1. Th	1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.					
2. Th	2. This REPORT consists of a total of 6 sheets, including this cover sheet.					
3. Th	nis report is also accomp	panied by ANNEXES, comprising	g:			
a.	(sent to the ap	pplicant and to the International l	Bureau) a total of 4	sheets, as follows:		
	sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental					
ъ.	Box.  b. Sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))					
0.	•		or (indicate type and numi	per of electronic carrier(s))		
	1 flexible disk , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
4. Tì	nis report contains indic	ations relating to the following it	ems:			
	Box No. I	Basis of the report				
l F	Box No. II	Priority				
Ì 7	Box No. III	•	ith as assaul to morroller, imres	meiricantum and individual amplicability		
	<b>¬</b>	·	mi regard to noverty, inve	ntive step and industrial applicability		
	Box No. IV Lack of unity of invention  Box No. V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;					
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
	Box No. VI Certain documents cited					
	Box No. VII	Certain defects in the internation	al application			
Box No. VIII Certain observations on the international application						
Date of submission of the demand  Date of completion of this report						
			2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2			
Name and mailing address of the IPEA/JP			Authorized officer			
Facsimile No.		Telephone No				

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/004190

Box	No. I	Basis of the report		
1.		regard to the language, this report is based on the internation ated under this item.	al application in the language in	which it was filed, unless otherwise
		This report is based on translations from the original language which is the language of a translation furnished for the purportion		,
		international search (Rule 12.3 and 23.1(b))		
		publication of the international application (Rule 12.4)		
	337141	international preliminary examination (Rule 55.2 and/o	•	hand which have been forwished to the
2.	recei	regard to the <b>elements</b> of the international application, this r iving Office in response to an invitation under Article 14 are report):		
		the international application as originally filed/furnished		
	$\boxtimes$	the description:		
		pages 1,2,5-23		as originally filed/furnished
		pages* _ 3,3/1,4	received by this Authority on	26.01.2005
		pages*	received by this Authority on	
	$\boxtimes$	the claims:		
		nos. 7-10		as originally filed/furnished
		nos.*	as amended (togethe	r with any statement) under Article 19
		nos.* _ 1-6	received by this Authority on	26.01.2005
		nos.*	received by this Authority on	
	$\boxtimes$	the drawings:		
		sheets 1/11-11/11		as originally filed/furnished
		sheets*	received by this Authority on	
		sheets*		
	$\boxtimes$	a sequence listing and/or any related table(s) - see Supplem		isting
\			ental Box Relating to Bequeites 1	Jisting.
3.	ш	The amendments have resulted in the cancellation of:		
		the description, pages		
		the claims, nos.		<u> </u>
1				
		the sequence listing (specify):		
4.		This report has been established as if (some of) the amend they have been considered to go beyond the disclosure as fi		
		the description, pages		
		the claims, nos.		
		the drawings, sheets/figs		
		the sequence listing (specify):		
		any table(s) related to sequence listing (specify):		
*	If it	tem 4 applies, some or all of those sheets may be marked "sup	erseded."	

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/004190

Bo		Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
1.	Statement			
	Novelty (N)	Claims	1-10	YES
		Claims		NO
	Inventive step (IS)	Claims	1-10	YES
		Claims		NO
	Industrial applicability	(IA) Claims	1-10	YES
		Claims		NO

#### 2. Citations and explanations (Rule 70.7)

- Document 1: The Journal of General Physiology, Vol. 115, No. 5, 2000, pages 583 to 598
- Document 2: WO 01/76618 A1 (Univ. New York State Res. Found.), 18 October 2001
- Document 3: Nature, Vol. 409, No. 6816, 2001, pages 35 to 36

The invention that is set forth in claims 1 to 10 is not disclosed in any of documents 1 to 3, which are cited in the international search report; therefore, the invention in question is novel and involves an inventive step.

International application No.
PCT/JP2004/004190

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

#### 1. Claim 3

The polypeptides (or salts thereof) that are set forth in claim 3 are characterized in that: they comprise an "amino acid sequence that is configured by deleting, substituting inserting or adding one or a plurality of amino acids" within the amino acid sequences that are represented by SEQ ID NO: 1 and SEQ ID NO: 2; they form intramolecular disulfide bonds; and they exhibit an activity whereby they inhibit mechano-sensitive channels.

Therein, the number of amino acids within the amino acid sequences that are represented by SEQ ID NO: 1 and SEQ ID NO: 2 are as follows: the amino acid sequence that is represented by SEQ ID NO: 1 comprises 10 amino acids, and the amino acid sequence that is represented by SEQ ID NO: 2 comprises 8 amino acids. Therefore, deleting amino acids at arbitrary positions, substituting amino acids at arbitrary positions with an arbitrary amino acid from among the approximately 20 types of existing amino acids, or inserting and/or adding (an) arbitrary amino acid(s) at arbitrary positions within these amino acid sequences will give a large number of amino acid sequences that have a structure which is capable of forming intramolecular disulfide bonds, regardless of whether or not these amino acid sequences exhibit an activity whereby they inhibit mechano-sensitive channels (ultimately, since it is sufficient that an intramolecular disulfide bond be formed, the Cys molecules within SEQ ID NO: 1 or 2 can be substituted freely as long as there are two Cys molecules at arbitrary positions so that in the end an intramolecular

International application No.
PCT/JP2004/004190

Box No. VIII Certain observations on the international application

disulfide bond will be formed).

Consequently, it is thought that a person skilled in the art would have to carry out a excessive amount of screening and experimentation in order to select the amino acid sequences that exhibit an activity whereby they inhibit mechano-sensitive channels from among this large number of amino acid sequences, even with consideration of common technical knowledge at the time the present application was filed.

As a result, the detailed description of the present invention cannot be considered to be disclosed in a manner that is sufficiently clear and complete for the invention that is set forth in claim 3 to be carried out by a person skilled in the art.

### 2. Claims 9 and 10

The inventions set forth in claims 9 and 10 include inhibitors or therapeutic agents which comprise the polypeptides that are set forth in claim 3.

Consequently, due to the fact that the polypeptides that are set forth in claim 3 suffer from the defects that are indicated in section 1, above, the inventions set forth in claims 9 and 10, which include inhibitors or therapeutic agents that comprise the polypeptides that are set forth in claim 3, will also suffer from the same defects as are indicated above.

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/004190

Supplemental Box Relating to Sequence Listing					
Continuation of Box No. I, item 2:					
1.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis of:				
	a. type of material  a sequence listing				
	table(s) related to the sequence listing  b. format of material  in written format  in computer readable form				
	c. time of filing/furnishing  contained in the international application as filed  filed together with the international application in computer readable form  furnished subsequently to this Authority for the purposes of search and/or examination  received by this Authority as an amendment* on				
2.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.				
	If item 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked "superseded."				